Pro-urokinase for Extended-Window Posterior Circulation Stroke

Summary

This study aims to evaluate whether, in patients with imaging-confirmed acute ischemic stroke of the posterior circulation presenting within 4.5-24 hours after symptom onset and not scheduled for endovascular thrombectomy, intravenous thrombolysis with recombinant human prourokinase (rhPro-UK), compared with standard medical treatment, can achieve superior 90-day functional outcomes with a higher level of safety.

Timeline

Start

2026-06-01

Primary completion

2027-12-31

Completion

2028-06-30

Drugs

Indications